COL17A1
CRISPR/Cas9
gene editing
gene therapy
homology-directed repair (HDR)
junctional epidermolysis bullosa (JEB)
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
06
2022
accepted:
01
08
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
epublish
Résumé
Epidermolysis bullosa (EB), a severe genetic disorder characterized by blister formation in skin, is caused by mutations in genes encoding dermal-epidermal junction proteins that function to hold the skin layers together. CRISPR/Cas9-induced homology-directed repair (HDR) represents a promising tool for editing causal mutations in In this study, we treated primary type XVII collagen (C17)-deficient JEB keratinocytes with either Cas9 nuclease or nickase (Cas9n) ribonucleoproteins (RNP) and a single-stranded oligonucleotide (ssODN) HDR template in order to correct a causal pathogenic frameshift mutation within the As analyzed by next-generation sequencing of RNP-nucleofected keratinocytes, we observed an HDR efficiency of ∼38% when cells were treated with the high-fidelity Cas9 nuclease, a mutation-specific sgRNA, and an ssODN template. The combined induction of end-joining repair and HDR-mediated pathways resulted in a C17 restoration efficiency of up to 60% as assessed by flow cytometry. Furthermore, corrected JEB keratinocytes showed a significantly increased adhesive strength to laminin-332 and an accurate deposition of C17 along the basement membrane zone (BMZ) upon differentiation into skin equivalents. Here we present a gene editing approach capable of reducing end joining-generated repair products while increasing the level of seamless HDR-mediated gene repair outcomes, thereby providing a promising CRISPR/Cas9-based gene editing approach for JEB.
Sections du résumé
Background
UNASSIGNED
Epidermolysis bullosa (EB), a severe genetic disorder characterized by blister formation in skin, is caused by mutations in genes encoding dermal-epidermal junction proteins that function to hold the skin layers together. CRISPR/Cas9-induced homology-directed repair (HDR) represents a promising tool for editing causal mutations in
Methods
UNASSIGNED
In this study, we treated primary type XVII collagen (C17)-deficient JEB keratinocytes with either Cas9 nuclease or nickase (Cas9n) ribonucleoproteins (RNP) and a single-stranded oligonucleotide (ssODN) HDR template in order to correct a causal pathogenic frameshift mutation within the
Results
UNASSIGNED
As analyzed by next-generation sequencing of RNP-nucleofected keratinocytes, we observed an HDR efficiency of ∼38% when cells were treated with the high-fidelity Cas9 nuclease, a mutation-specific sgRNA, and an ssODN template. The combined induction of end-joining repair and HDR-mediated pathways resulted in a C17 restoration efficiency of up to 60% as assessed by flow cytometry. Furthermore, corrected JEB keratinocytes showed a significantly increased adhesive strength to laminin-332 and an accurate deposition of C17 along the basement membrane zone (BMZ) upon differentiation into skin equivalents.
Conclusion
UNASSIGNED
Here we present a gene editing approach capable of reducing end joining-generated repair products while increasing the level of seamless HDR-mediated gene repair outcomes, thereby providing a promising CRISPR/Cas9-based gene editing approach for JEB.
Identifiants
pubmed: 36091706
doi: 10.3389/fmed.2022.976604
pmc: PMC9454317
doi:
Types de publication
Journal Article
Langues
eng
Pagination
976604Informations de copyright
Copyright © 2022 Petković, Bischof, Kocher, March, Liemberger, Hainzl, Strunk, Raninger, Binder, Reichelt, Guttmann-Gruber, Wally, Piñón Hofbauer, Bauer and Koller.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Exp Dermatol. 2003 Jan;28(1):53-60
pubmed: 12558632
Cell Rep. 2020 Mar 17;30(11):3932-3947.e6
pubmed: 32187560
Mol Ther Nucleic Acids. 2021 May 29;25:237-250
pubmed: 34458008
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
Mol Ther. 2022 Aug 3;30(8):2664-2679
pubmed: 35690907
Bioinformatics. 2017 Jan 15;33(2):286-288
pubmed: 27559154
Mol Ther Nucleic Acids. 2019 Dec 6;18:496-507
pubmed: 31670199
J Invest Dermatol. 2019 Aug;139(8):1699-1710.e6
pubmed: 30998984
J Invest Dermatol. 2020 Oct;140(10):1985-1993.e5
pubmed: 32142798
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
J Invest Dermatol. 2020 Feb;140(2):338-347.e5
pubmed: 31437443
Nature. 2019 Apr;568(7752):344-350
pubmed: 30944469
Nature. 2017 Nov 16;551(7680):327-332
pubmed: 29144448
Trends Biochem Sci. 2015 Nov;40(11):701-714
pubmed: 26439531
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
Mol Ther Methods Clin Dev. 2017 Jul 05;6:112-123
pubmed: 28765827
Mol Ther. 2017 Nov 1;25(11):2573-2584
pubmed: 28800953
Mol Ther. 2022 Aug 3;30(8):2680-2692
pubmed: 35490295
Am J Pathol. 2011 Aug;179(2):829-37
pubmed: 21801871
Br J Dermatol. 2020 Oct;183(4):614-627
pubmed: 32017015
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Med. 2022 Apr;28(4):780-788
pubmed: 35347281
Mol Ther. 2017 Nov 1;25(11):2585-2598
pubmed: 28888469
J Invest Dermatol. 2017 Mar;137(3):778-781
pubmed: 27840234
Nat Med. 2006 Dec;12(12):1397-402
pubmed: 17115047